The Economic Burden of Asthma in Canada

NCT03243110 | Completed

• 1 other identifier: H10-01542
• Study Type: observational
• Target: 613
• Locations: 0 countries
• Sites: N/A

Brief Summary

The study will consist of three phases: Phase A: General population survey for estimation of the prevalence of asthma, and prospective collection of resource utilization and quality-of-life data for 12 months, Phase B: comparison of healthcare resource usage collected prospectively to the data collected using administrative data in the population recruited in Phase A, and Phase C: Economic modeling of asthma to extrapolate the findings across Canada and into the future years.

Conditions

Asthma

Outcome Measures

Primary Outcomes (1)

• Costs of asthma in BC and Canada per patient

  Costs per patients will be calculated by multiplying the amount of healthcare resources used by the corresponding unit costs. The investigators will adjust all unit costs to 2010 Canadian dollar according to the medical care component of the Consumer Price Index(42). The lowest price for available (generic drugs if exists) versions of medications will be used based on province-specific data.

  September 2013

Secondary Outcomes (2)

• Calculating quality of life of participants with asthma using the Asthma Quality of Life Questionnaire

  January 2017

• Calculating quality of life of participants with asthma using the EuroQol's EQ-5D Questionnaire

  February 2017

Study Arms (1)

Asthmatics requiring breathing test

Participants must have had a diagnosis of asthma by a physician. The participant must have had a self-reported health care interaction related to asthma (physician visit, ED visit, hospitalization) in the past 5 years. Participants must be 1 to 85 years old.

Diagnostic Test: breathing test

Interventions

breathing test DIAGNOSTIC_TEST

Spirometry is a non-invasive means of measuring lung function: The participant is asked to take a deep breath and then exhale into the sensor as hard and as long as possible. Soft nose clips may be used to prevent air escaping through the nose. If the participant does not show a definitive diagnosis of asthma, a methacholine challenge test will be performed to elicit bronchoconstriction in participants. In methacholine challenge test, the participant breaths in standardized dose of nebulized methacholine again. Methacholine challenge test is widely accepted and standardized method for assisting the diagnosis of asthma and there will be no experimental altercation in the method methacholine challenge is performed.

Asthmatics requiring breathing test

Eligibility Criteria

• Age: 1 Year - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Phase A of the study will be based on the survey of the general population (1-85 y/o) of two well-defined target areas and recruitment of those with a self-reported physician diagnosis of asthma. Phase B of the study is the retrospective elicitation of the health record of participants. In Phase C of the study builds upon the data of Phase A and B and other published studies to extrapolate the results to the Canadian population for the next 10 years, as such it does not involve direct population sampling.

You may qualify if:

• Patient must state that they have had a diagnosis of asthma by a physician. In addition, the patient must have had a self-reported health care interaction related to asthma (physician visit, ED visit, hospitalization) in the past 5 years.
• Patient must be 1 to 85 years old.

You may not qualify if:

• Patients unable to provide informed consent due to language difficulties or cognitive impairment.
• Patients who have a greater than 10 pack-year smoking history (this will exclude patients with possible COPD).
• Patients who know that they will be moving out of the province within 12 months of study entry.
• Patients in whom metacholine challenge test is contraindicated due to non-asthma-related reasons (e.g. patients with cerebral aneurysm, pregnant and breastfeeding participants).

Sponsors & Collaborators

• University of British Columbia: lead
• GlaxoSmithKline: collaborator

MeSH Terms

Conditions

Asthma

Interventions

Breath Tests

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Intervention Hierarchy (Ancestors)

Diagnostic Techniques and Procedures; Diagnosis

Study Officials

• Mohsen Sadatsafavi, MD,Ph.D

  University of British Columbia

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: August 3, 2017
• First Posted: August 8, 2017
• Study Start: December 1, 2010
• Primary Completion: September 1, 2013
• Study Completion: June 1, 2017
• Last Updated: November 13, 2017

Record last verified: 2017-08